Open AccessChoice of optimal therapeutic sequence in treatment of patients with progressive / metastatic squamous cell cancer of the head and neck in the light of TPEx study results
Author(s) -
А М Мудунов
Publication year - 2022
Publication title -
opuholi golovy i šei
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.14
H-Index - 1
eISSN - 2411-4634
pISSN - 2222-1468
DOI - 10.17650/2222-1468-2021-11-4-58-63
Subject(s) - medicine , regimen , cetuximab , hazard ratio , docetaxel , chemotherapy , head and neck cancer , oncology , squamous cell cancer , chemotherapy regimen , surgery , confidence interval , performance status , radiation therapy , cancer , colorectal cancer
KEYNOTE-048 study results became basis for changing standard of care in the 1 st line treatment of patients with recurrent / metastatic squamous cell cancer of the head and neck (SCCHN). However, there were no significant improvement in the progression free survival for patients receiving pemrolizumab as a monotherapy or in combination with chemotherapy in both group of patients, with PD-L expression (CPS >1) and without it (CPS 20) in total population. Post-hoc analysis of TPExtreme study demonstrated the most benefit results until now for patients who received consequently cetuximab contained chemotherapy regimens as a first line followed by immunotherapy for the second line in this patients group (overall survival 19.4 months for EXTREME arm and 21.9 months for TPEx arm). Thus TPExtreme study results demonstrates opportunity for better disease control in patients receiving cetuximab in first line and immunotherapy as second line treatment in total population for patients with recurrent / metastatic SCCHN.